

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1614
Examiner : Jagoe, Donna A.
Applicant(s) : Nancy Jean Britten, et. al.
Serial Number : 10/803,146
Filed : March 17, 2004
Confirmation No. : 5036
Customer No. : 25533
For : Dispersible Formulation of An Anti-Inflammatory Agent

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

In response to the election/restriction requirement dated September 20, 2007,
please amend the above-identified application as follows:

Restriction/elections begin on page 2 of this paper.

Amendments to the claims are reflected in the listing of claims which begin on page 3 of
this paper.

Remarks/arguments begin on page 7 of this paper.

RESTRICTION/ELECTIONS

In response to the restriction requirement, Applicants elect Group II, that is, Claims 25-58, drawn to a pharmaceutical composition. In response to the Examiner's request that Applicants select a single inflammatory condition or bacterial disease and one anti-inflammatory agent for prosecution, Applicants select mastitis as the inflammatory condition or bacterial disease and celecoxib as the anti-inflammatory agent.